Free Trial

McKesson (MCK) Competitors

$569.59
+8.63 (+1.54%)
(As of 05/31/2024 ET)

MCK vs. COR, CAH, HSIC, PDCO, OMI, HLF, NUS, PETQ, HWH, and BIMI

Should you be buying McKesson stock or one of its competitors? The main competitors of McKesson include Cencora (COR), Cardinal Health (CAH), Henry Schein (HSIC), Patterson Companies (PDCO), Owens & Minor (OMI), Herbalife (HLF), Nu Skin Enterprises (NUS), PetIQ (PETQ), HWH International (HWH), and BIMI (BIMI).

McKesson vs.

Cencora (NYSE:COR) and McKesson (NYSE:MCK) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk, institutional ownership and community ranking.

Cencora pays an annual dividend of $2.04 per share and has a dividend yield of 0.9%. McKesson pays an annual dividend of $2.48 per share and has a dividend yield of 0.4%. Cencora pays out 22.3% of its earnings in the form of a dividend. McKesson pays out 11.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cencora has raised its dividend for 14 consecutive years and McKesson has raised its dividend for 16 consecutive years.

97.5% of Cencora shares are owned by institutional investors. Comparatively, 85.1% of McKesson shares are owned by institutional investors. 15.8% of Cencora shares are owned by company insiders. Comparatively, 0.2% of McKesson shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cencora has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Comparatively, McKesson has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500.

McKesson received 214 more outperform votes than Cencora when rated by MarketBeat users. Likewise, 74.16% of users gave McKesson an outperform vote while only 65.12% of users gave Cencora an outperform vote.

CompanyUnderperformOutperform
CencoraOutperform Votes
730
65.12%
Underperform Votes
391
34.88%
McKessonOutperform Votes
944
74.16%
Underperform Votes
329
25.84%

In the previous week, McKesson had 22 more articles in the media than Cencora. MarketBeat recorded 36 mentions for McKesson and 14 mentions for Cencora. Cencora's average media sentiment score of 0.62 beat McKesson's score of 0.09 indicating that McKesson is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cencora
4 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
McKesson
12 Very Positive mention(s)
8 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

McKesson has a net margin of 0.97% compared to McKesson's net margin of 0.67%. McKesson's return on equity of 268.67% beat Cencora's return on equity.

Company Net Margins Return on Equity Return on Assets
Cencora0.67% 268.67% 4.13%
McKesson 0.97%-245.88%5.57%

McKesson has higher revenue and earnings than Cencora. Cencora is trading at a lower price-to-earnings ratio than McKesson, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cencora$262.17B0.17$1.75B$9.1424.79
McKesson$308.95B0.24$3.00B$22.3825.45

Cencora presently has a consensus price target of $233.90, indicating a potential upside of 3.24%. McKesson has a consensus price target of $571.47, indicating a potential upside of 0.33%. Given McKesson's higher possible upside, analysts clearly believe Cencora is more favorable than McKesson.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cencora
0 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.70
McKesson
0 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.87

Summary

McKesson beats Cencora on 15 of the 21 factors compared between the two stocks.

Get McKesson News Delivered to You Automatically

Sign up to receive the latest news and ratings for MCK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MCK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MCK vs. The Competition

MetricMcKessonDrugs, proprietaries, & sundries IndustryMedical SectorNYSE Exchange
Market Cap$74.04B$15.07B$5.11B$17.81B
Dividend Yield0.44%1.29%2.75%3.55%
P/E Ratio25.4516.81120.3622.67
Price / Sales0.241.912,428.4511.15
Price / Cash17.099.7835.0418.95
Price / Book-46.318.605.525.90
Net Income$3.00B$618.02M$105.88M$976.46M
7 Day Performance1.58%1.88%1.13%0.62%
1 Month Performance7.23%1.31%1.42%4.79%
1 Year Performance46.34%2.78%4.04%24.00%

McKesson Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
COR
Cencora
4.2082 of 5 stars
$216.21
-1.2%
$233.90
+8.2%
+33.1%$43.12B$262.17B23.6646,000Insider Buying
CAH
Cardinal Health
4.0695 of 5 stars
$94.77
-1.7%
$107.57
+13.5%
+20.6%$23.08B$205.01B42.1248,000Analyst Downgrade
Short Interest ↓
HSIC
Henry Schein
3.8665 of 5 stars
$71.15
-0.8%
$81.73
+14.9%
-6.2%$9.11B$12.45B24.0425,000Short Interest ↑
Analyst Revision
PDCO
Patterson Companies
4.297 of 5 stars
$23.98
+0.2%
$31.67
+32.1%
-6.1%$2.15B$6.47B11.817,600Analyst Downgrade
Analyst Revision
OMI
Owens & Minor
4.6215 of 5 stars
$17.29
-1.4%
$23.29
+34.7%
-14.2%$1.32B$10.33B-33.9013,700Positive News
HLF
Herbalife
3.3707 of 5 stars
$10.82
+0.6%
$10.50
-2.9%
-13.0%$1.08B$5.06B7.899,200Analyst Upgrade
NUS
Nu Skin Enterprises
4.7386 of 5 stars
$13.34
+0.8%
$20.83
+56.2%
-59.9%$662.35M$1.97B-222.213,700Positive News
PETQ
PetIQ
3.8271 of 5 stars
$19.91
+0.6%
$29.00
+45.7%
+63.1%$592.32M$1.10B90.501,933Positive News
HWH
HWH International
0 of 5 stars
$1.30
+10.2%
N/AN/A$21.09MN/A0.00N/AShort Interest ↓
Positive News
Gap Down
BIMI
BIMI
0 of 5 stars
$1.09
+1.9%
N/A+19.6%$12.63M$11.83M0.00296Upcoming Earnings
Short Interest ↓

Related Companies and Tools

This page (NYSE:MCK) was last updated on 6/1/2024 by MarketBeat.com Staff

From Our Partners